- Program Target
- SNCA x IGF1R
- Disease Indication
- Parkinson’s Disease
- Development Stage
- Late-Stage Research
- Propagation of aggregated form of alpha synuclein (α-syn) appears to be critical for etiology of Parkinson’s disease and multiple system atrophy. ABL301 specifically targets aggregated forms of α-syn, potential disease target, Devoid of its normal, monomeric form.
Since poor delivery of antibody into the brain is thought to be one of the major obstacles for CNS-related drug development, ABL301 has a shuttle antibody to allow improved delivery of antibody therapeutics into the brain.
These dual mechanisms will provide more efficient reach of antibody therapeutics to its target, leading to better therapeutic Efficacy than conventional monoclonal antibody.